“EFFECT OF PRE-OPERATIVE GABAPEHTIN ON EARLY POST OPERATIVE PAIN, NAUSEA, VOMITING AND ANALGESIC CONSUMPTION FOLLOWING HYSTERECTOMY IN A TERTIARY CARE TEACHING HOSPITAL: A RANDOMIZED CONTROLLED TRIAL”

Debasis Ray1,*, Samiksha Bhattacharjee2

1Associate Professor, Dept. of Pharmacology, Govt. Medical College, Agartala, Tripura, India, 2JR, Agartala Govt. Medical College, Agartala, Tripura, India.

*Corresponding Author:
E-mail: contactdebasirs@gmail.com

ABSTRACT

Introduction: Gabapentin is not normally used for post-operative pain relief. Presently available data suggest that pre-operative Gabapentin may play role in the management of post operative pain but more work is necessary before recommending it for routine clinical use. So present study was taken up with the objective to evaluate the effects of pre operative Gabapentin on postoperative pain, nausea, vomiting and analgesic consumption.

Methods: A double blind, parallel group, placebo controlled randomized control trial was conducted among 60 patients (30 each in each group) undergoing abdominal hysterectomy to see the effect of 2 hour pre operative administration of single dose of Gabapentin (300 mg) on post operative pain and analgesic consumption. Severity of pain, nausea, vomiting and total analgesic consumption was compared between the two study groups at 4, 24 and 48 after operation.

Results: Statistically significant less median pain score in VAS were seen in Gabapentin group than in placebo group subjects at all time points. Post operatively at 4 hrs and 24 hrs the total dose of analgesic consumption were statistically lower in Gabapentin group (p<0.5) than placebo group. There was no statistically significant difference of nausea and vomiting at 4, 24 and 48 hours post operatively between Gabapentin and placebo group subjects. No patient in any group reported any adverse effects.

Conclusions: This study suggests that pre-operative gabapentin has clinical potential in management of early post operative pain. Low dose Gabapentin (300 mg) can be used as a preemptive analgesic before abdominal Hysterectomy.

Keywords: Gabapentin, Post-operative pain, VAS, Hysterectomy.

INTRODUCTION

Post operative pain is the greatest fear of patients who undergo any surgical procedure. Prevention and treatment of post operative pain and complications such as post operative nausea and vomiting (PONV) continues to be a major challenge in post operative care and plays an important role in the early mobilization and well being of the surgical patients.[1]

The degree of postoperative pain, perceived by the patient, is multi factorial and depends on variables such as type and duration of the operation, type of anaesthesia and analgesia used, and the patient’s mental and emotional state. If sufficient analgesia is provided, not only will the patient’s comfort be increased but the duration of hospital stay will be shortened, reducing both treatment costs and the risk of hospital-acquired infections. Of the many methods of postoperative pain relief, the oldest and most widely used is parenteral opioids.[2]

Opioid analgesics are frequently used for postoperative analgesia, but their use is limited by their side effects. The mechanisms involved in pain suggest that a combination of non-opioid analgesics and opioids might enhance the quality of analgesia and reduce opioid requirements and side-effects. However, non-steroidal anti-inflammatory drugs, which would otherwise be ideal for administration in combination with opioids, have adverse effects on the gastro-intestinal and haematological systems as well as on renal function.[2]

Hysterectomy is one of the most common types of surgery. Hysterectomy is still the only definitive treatment of dysfunctional uterine bleeding (DUB) and, compared with most other alternative therapies, has acceptable satisfaction. In the majority of cases, hysterectomy is performed through the abdomen, although in many cases, vaginal surgery is considered less complicated than abdominal hysterectomy.[3]

Gabapentin, a structural analogue of gamma-amino butyric acid, is used as an anticonvulsant drug. In addition, it has been effective in neuropathic pain, diabetic neuropathy, post herpetic neuralgia, and reflex sympathetic dystrophy. Pre-treatment with Gabapentin can block the development of hyperalgesia.[4]

Gabapentin does not interact with other commonly prescribed drugs. Its most frequent side-effects are somnolence, dizziness and fatigue, which are also common side-effects of widely used pre medications. In addition, the side-effects of Gabapentin are usually not severe.[2]
Several studies have been done about the possible effect of Gabapentin on postoperative pain. Available data suggest that Gabapentin may indeed have a place in the management of post operative pain. However, considerably more work is required before recommending it for routine clinical use preoperatively for post operative pain relief. Considering the above facts present study was taken up with the Primary Objective to measure and compare the pain score by Visual analogue scale (VAS) at rest at 4, 24 & 48 hour postoperatively after hysterectomy under Spinal Anesthesia following single 2 hour pre-operative dose of 300 mg Gabapentin orally and Secondary Objectives were: i. To assess the total analgesic consumption in 4, 24 & 48 hours after hysterectomy following preoperative administration of Gabapentin, ii. To identify the time of patient’s first request for supplemental analgesia after hysterectomy following preoperative administration of Gabapentin and iii. To evaluate the effects of preoperative administration of Gabapentin on postoperative nausea, vomiting, after hysterectomy on a 4 point verbal scale (Absent, mild, moderate and severe).

MATERIALS AND METHODS
1. Trial Design: This was a single centred, double blind, placebo controlled, randomized control trial (RCT) of pre-operative 300mg gabapentin orally compared with placebo in subjects undergoing elective abdominal hysterectomy operation for prevention of post operative pain, nausea and vomiting and analgesic consumption.
2. Ethical Committee Approval: Institutional ethical committee approval was taken.
3. Trial Registration: Trial was registered in Clinical Trial Registry of India (CTRI) vide No. CTRI/2012/05/002700.
4. Participants- Inclusion Criteria:
   a. 18 yrs or older.
   b. Patient with American Society of Anesthesiologists (ASA) classification grade I & Grade II will be included.
   c. Undergoing elective abdominal hysterectomy under spinal anesthesia at tertiary care teaching hospital.

Exclusion Criteria:
   a. Patients with present history of pregnancy.
   b. Patients with history of epilepsy or chronic pain, or use of anti epileptic drugs or neuropathic analgesics.
   c. Patient with American Society of Anesthesiologists (ASA) classification of 3 or greater.
   d. Patients with a history of opioid or intravenous drug abuse.
   e. Patients with known allergy to gabapentin.

f. Patients who have taken antacid medication in the previous 24 hrs.
g. Patients who refused spinal anaesthesia.
5. Study Area: Gynaecology ward and including preoperative and post operative care room of the Tertiary care Hospital.
6. Interventions: Patients were screened and satisfying inclusion criteria were recruited in the present study after written informed consent. A total of 60 patients of either sex were selected randomly by permuted variable block randomization, and assigned to receive either 300 mg of Gabapentin[3] or a matched placebo[6] (collected from KC Laboratories, Mumbai) in 1:1 ratio, orally 2 hr before spinal anaesthesia in a double blind manner. All the patients, both control and Gabapentin group were anesthetized under Spinal anaesthesia according to the standard institutional protocol after similar premedication. Single dose of 50 mg i.m injection Diclofenac sodium was provided in all subjects immediately after operation. All the subjects were assessed for pain at rest at 4, 24 & 48 hrs[7,8,9] post operatively by visual analogue scale score (VAS) (0 mm: no pain,100 mm: Worst pain imaginable).[2] They also were evaluated for nausea, vomiting, drowsiness, and pruritus and rated on a four point verbal scale (none, mild, moderate, severe) at 4, 24, 48 hrs.[12] Total rescue analgesic consumption also was assessed at 4, 24, 48 hrs post operatively.[2] The time of patient’s first request for supplemental analgesia also was recorded. Injection Diclofenac sodium 50mg per dose i.m. was given as supplemental analgesic.

7. Outcome Variables:
   a. Primary Outcome Variable: Pain score by 100 point visual analogue scale at 4, 24 and 48 hours post operatively.
   b. Secondary Outcome Variable:
      a) Total dose of analgesic consumption was measured at 4, 24 & 48 hours post operatively.
      b) Request of 1st supplementary analgesia post operatively by the patient was recorded in terms of minutes.
      c) Grading of nausea and vomiting post operatively at 4, 24 & 48 hours were measured using 4 point verbal scale. (None, mild, moderate, severe).
      d) No changes in trial outcome were made after commencement of the trial.
8. Sample Size & Sampling Unit: A sample size of 30 in each group assumed to be sufficient to detect a clinically important difference of (μ1−μ2) 20 points on the VAS scale of pain, assumed a standard deviation(σ) 20 with a power of 90% and a significance level of 1%. A total of 60 patients (30 placebo group and 30 Gabapentin group) who have undergone elective abdominal
hysterectomy operation under spinal anaesthesia (SA) were selected randomly from the gynaecology ward of the tertiary care Hospital. Sample size calculation done by the following formula.

\[ n = \frac{2[(a + b)^2 \sigma^2]}{(\mu_1 - \mu_2)^2} \]

\[ n = 2((2.58 +1.28)^2 \times 20^2) \quad n = 30 \text{ (in each group)} \]

(Values are of VAS of pain)

9. Randomization:
   a. **Sequence Generation**: Permutated variable block randomization.
   b. **Allocation Concealment Mechanism**: Sequentially numbered sealed opaque envelope.
   c. **Implementation**: Random allocation sequence was generated by a faculty member of the Dept. of Community Medicine independent to investigator. Participants were enrolled and assigned intervention by a particular investigator.
   d. **Blinding**: Double blind (both patient and investigator) by matched placebo

10. **Statistical Methods**: Statistical analysis was done for significant difference for reduction of pain in VAS, nausea, vomiting and analgesic consumption post operatively between the control group and Gabapentin group population. Pain score (observed in VAS) was analyzed using Man-Whitney test. Total analgesic consumption and time of request of 1st supplementary analgesia were calculated of significance by Independent “t test”. Nausea and Vomiting, being categorical variables were analyzed by Pearson Chi-square test.

11. **Study overview & treatment arms**:

   ![Diagram showing study overview and treatment arms]

   - VAS at 4, 24, 48 hours post operatively at rest.
   - PONV, drowsiness & pruritus at 4, 24, 48 hours.
   - Total dose of analgesic consumption at 4, 24, 48 hour.
   - Time of 1st request of the patient for analgesic.

   **Gabapentin allocation**
   - 2 hr pre-operatively N = 30

   **Placebo allocation**
   - 2 hr pre-operatively N = 30

   Analysis N=30

No subjects were lost after randomization and all completed the study.
RESULTS
Total 60 patients, 30 of gabapentin and 30 of placebo group consented and participated and completed the study, conducted w.e.f. April 2013 to Sept 2013. To avoid the variability in the different surgical procedures of different indications, the patients who had undergone hysterectomy, done under spinal anaesthesia in our hospital had been considered for this study. There was no significant difference in the demographic data like age and also in the clinical data like ASA classification, duration of anaesthesia, types of operation. (Table -1)

Table 1: Demographic and pre operative data in the two study groups

<table>
<thead>
<tr>
<th>Variables</th>
<th>Gabapentin N=30</th>
<th>Placebo N=30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Mean ± SD)</td>
<td>43.13 ± 11.27</td>
<td>44.10 ± 10.76</td>
</tr>
<tr>
<td>ASA1:ASA2</td>
<td>20:10</td>
<td>18:12</td>
</tr>
<tr>
<td>Types of operation.</td>
<td>Hysterectomy</td>
<td>Hysterectomy</td>
</tr>
<tr>
<td>Duration of anaesthesia in terms of hrs. (Mean ±SD)</td>
<td>2.86 ± 0.80</td>
<td>2.76 ± 0.98</td>
</tr>
</tbody>
</table>

* ASA 1 & 2=American society of Anesthesiologists classification grade 1 and 2.

Table 2: Pain score in VAS after preoperative Gabapentin at 4, 24, 48 hrs post operatively.

<table>
<thead>
<tr>
<th>Trial Medication</th>
<th>Gabapentin (N=30)</th>
<th>Placebo (N=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain scores at;</td>
<td>Mean ± SD</td>
<td>Median Percentile (25, 75)</td>
</tr>
<tr>
<td>4 hrs *</td>
<td>56.16±14.24</td>
<td>57.50 50, 62.50</td>
</tr>
<tr>
<td>24 hrs *</td>
<td>37.00±12.56</td>
<td>40.00 30, 50</td>
</tr>
<tr>
<td>48 hrs **</td>
<td>18.33±13.21</td>
<td>20.00 10, 30</td>
</tr>
</tbody>
</table>

* p< 0.001 (Gabapentin vs Placebo) & ** p=0.672 (Gabapentin vs Placebo) (As per Man Whitney test).

Table 2 shows that after hysterectomy at 4, & 24 hours post operatively there were statistically significant less pain score in Gabapentin group than in placebo group subjects.

Fig. 1: Pain score in VAS at 4, 24, 48 hours post operatively following hysterectomy in preoperative Gabapentin and placebo group subjects.

Fig. 2: Total analgesic (TAC) consumption post operatively following hysterectomy in preoperative Gabapentin and placebo group subjects.
which causes a reduction in the
s had shown that similar dose of
ommonly prescribed drugs. Ava
ble data 

$st$ 4, 24 & 48 hrs post
he mean time
s
ntary
ent of hyperalgesia and central
abapentin group was at
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
in this study on a 4 point verbal scale, as described by the earlier investigators.\textsuperscript{[2, 7, 9]}

In this randomized placebo controlled study it has been found that oral administration of 300 mg Gabapentin as pre medication 2 hours before surgery decreased post operative pain, total analgesic consumption. The present study demonstrated that pre operative administration of Gabapentin significantly reduced the pain score in VAS postoperatively.\textsuperscript{(P < 0.001)} at 4 & 24 hrs and it is comparable with the findings of Sekhaitav et al. 2009, Chowdhuri L et al. 2012, Montazeri K et al. 2007 and Pandey CK et al. 2004 \textsuperscript{[1, 2, 10 - 12].}

In accordance with the findings of previous workers, Montazeri K et al. 2007, Sekhaitav L et al. 2009 and Pandey CK et al. 2004 \textsuperscript{[2, 11, 12]} in the present study total dose of analgesic consumption was also significantly less in all time intervals i.e. at 4, 24 & 48 hrs post operatively. The first request for supplementary analgesics were also significantly (p<0.01) delayed in Gabapentin group \textsuperscript{[2, 11].}

In the current study there was no significant difference in nausea and vomiting in both the study groups at different time intervals and this is probably because of low dose of Gabapentin. It is likely to be high dose Gabapentin that has anti-emetic effects.\textsuperscript{[2]}

Our findings regarding the incidence of nausea and vomiting at different time intervals are similar to those reported previously by Behdad S et al. 2012, Turan A et al. 2009, Dauri M et al. 2009 and Khademi S et al. 2010 \textsuperscript{[3, 4, 13, 14]}. As reported by the other workers in the present study also no significant adverse effect like drowsiness, pruritus, dizziness, somnolence, ataxia was recorded by the use of Gabapentin pre operatively \textsuperscript{[2, 7, 10].}

This study had the limitations of being conducted in single center, low study populations and less frequent pain score assessment in VAS at 4, 24 and 48 hours post operatively.

To conclude, this study showed that pre operative administration of low dose Gabapentin 300 mg 2 hrs before abdominal hysterectomy decreased post operative pain and total analgesic consumption and delayed the need of supplementary analgesics, suggesting that Gabapentin has clinical potential in the treatment of post operative pain without significant side effects.

ACKNOWLEDGEMENTS

This study was done under STS programme sponsored by ICMR. The authors are grateful to the ICMR and Principal, Agartala Govt. Medical College, Agartala, Tripura, for providing the necessary facilities to carry out this work. The authors are also grateful to K. C. Laboratories (Mumbai) for providing the sample of test drug Gabapentin and the matched placebo of Gabapentin to carry out this study.

REFERENCES


Ray et al.  
Effect of Pre-Operative Gabapentin on Early Post Operative Pain, Nausea, Vomiting and Analgesic...